First ever study of human stem cell treatment

The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
The U.S. Food and Drug Administration have approved an Investigational New Drug application from Geron Corporation. The company can now move forward with a ground-breaking clinical trial of a candidate called GRNOPC1 in patients with acute spinal cord injury. This will be world’s first study of a human stem cell treatment on human patients.

Geron plans to initiate a Phase I multi-center trial, designed to establish the safety of GRNOPC1 in patients with subacute thoracic spinal cord injuries. The study will be conducted in up to seven U.S. medical centers.

"This marks the beginning of what is potentially a new chapter in medical therapeutics - one that reaches beyond pills to a new level of healing: the restoration of organ and tissue function achieved by the injection of healthy replacement cells. The ultimate goal is to achieve restoration of spinal cord function by the injection of hESC-derived oligodendrocyte progenitor cells directly into the lesion site of the patient's injured spinal cord." says Thomas B. Okarma, Geron's president and CEO, in a press statement
Kommentera en artikel
Meddela redaktionen
Se alla medlemsnyheter
Mest läst
Senaste nytt
Se senaste nytt
Utvalda artiklar
Utvalda nyheter från förstasidan
Vicore tar in 200 miljoner — utvecklar behandling mot lungfibros
Stororder till samarbetspartner kan bli bingo för Raysearch
Ny Sverigechef till Boehringer Ingelheim
FDA kräver indraget tillstånd för Oncopeptides i USA
Uppmärksamheten kring ALS ger pengar till hennes forskning
Spago startar klinisk studie i endometrios
Andra Nordiska Medier
MedTech Magazine

Sänd till en kollega